| 标题： | 中国老年衰弱相关内分泌激素管理临床实践指南 |
| title： | Clinical practice guidelines for the management of endocrine hormones associated with frailty in the elderly in China |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | |
| Guide users： | |
| 证据分级方法： | 本指南推荐的条款根据循证医学的强度分为5级：A 强力推荐，证据肯定，能够改善健康结局，利大于弊；B 推荐，有很好证据，能够改善健康结局，利大于弊；C 不作推荐或者作为常规推荐，有证据能够改善健康结局但是利弊接近均等； D 反对推荐，因为证据不够有力或者对于健康结局弊大于利； I 缺乏证据，或者证据质量差，或者证据自相矛盾，无法确定对健康结局的利弊 |
| Evidence grading method： | The recommendations in this guideline are divided into five levels according to the strength of evidence-based medicine: A strong recommendation, positive evidence, can improve health outcomes, and the benefits outweigh the risks; B recommendation, which is well documented to improve health outcomes and does more good than harm; C Not recommended or routinely recommended, with evidence of improved health outcomes but with nearly equal benefits; D against recommendation because the evidence is not strong or would cause more harm than good to health outcomes; I Evidence is lacking, or of poor quality, or contradictory to determine the benefits and harms of health outcomes |
| 制定单位： | 中南大学湘雅二医院 |
| Formulating unit： | The Second Xiangya Hospital of Central South University |
| 注册时间： | 2022-08-09 |
| Registration time： | |
| 注册编号： | PREPARE-2022CN457 |
| Registration number： | |
| 指南制订的目的： | |
| Purpose of the guideline： |
